SEVERE MPOX AMONG PEOPLE LIVING WITH HIV RECEIVING TECOVIRIMAT IN NEW YORK CITY
Background: The mpox clinical course among people with HIV (PWH) during the 2022 outbreak is poorly understood. We describe mpox among PWH in New York City (NYC) who received >14 days of tecovirimat and/or coadministration of additional mpox treatments. Methods: We identified PWH with persistent or worsening mpox during tecovirimat treatment through healthcare providers who…